LexaGene to Host Webcast on July 14, 2020
July 08 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“Company”), a molecular diagnostics company that develops genetic
analyzers for rapid pathogen detection, is pleased to announce that
it will host a webcast investor presentation on Tuesday, July 14,
at 2:00 PM ET.
During the webcast, Dr. Jack Regan, LexaGene’s CEO and Founder,
will provide an introductory presentation through a PowerPoint
discussion that will cover key areas of LexaGene’s business,
including an overview of the Company’s proprietary technology,
target markets and opportunity, competitive advantages, growth
strategy, and anticipated milestones. Following the formal
presentation, investors will have an opportunity to ask relevant
questions through an interactive Q&A portal.
To listen to the webcast or to ask questions during the live
event, please pre-register at the following link:
https://event.webcasts.com/starthere.jsp?ei=1294081&tp_key=b029bb1560.
An archived version of the webcast and presentation will be
available on the investor relations section of the Company’s
website following the event.
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of Directors
Dr. Jack Regan Chief Executive Officer &
Director
About LexaGene Holdings Inc. LexaGene is a
molecular diagnostics company that develops genetic analyzers for
pathogen detection and other molecular markers for on-site rapid
testing in human clinical and veterinary diagnostics, food safety
and for use in open-access markets such as clinical research,
agricultural testing and biodefense. End-users simply need to
collect a sample, load it onto the instrument with a sample
preparation cartridge, enter sample ID and press ‘go’. The LX
Analyzer delivers excellent sensitivity, specificity, and breadth
of detection and can return results in about 1 hour. The unique
open-access feature is designed for custom testing so that
end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
For further information, please contact:
Media Contacts Nicole Ridgedale Director of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor Relations Jay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024